Compare Albertsons Companies Inc (ACI) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Bristol-Myers Squibb Co — how do they compare? Albertsons Companies Inc trades at $12.08 (market cap $5.95B), while Bristol-Myers Squibb Co trades at $63.55 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 21.8× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ACI | BMY | |
|---|---|---|
Market Cap | $5.95B | $129.94B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $65.89 |
52-Week Low | $11.03 | $42.60 |
Enterprise Value | $21.35B | $163.92B |
Dividend Yield | 5.55% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.13, up 1.0% on the day, but remains near multi-year lows after a sharp 22% drop following Q2 2026 earnings miss and lowered guidance. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $80.39B in 2025, but net income margin compressed to 0.08%, reflecting margin pressure. Recent news highlights CEO and CFO stock purchases, AI initiatives like the Safeway ChatGPT plugin, and ongoing shareholder litigation investigations.
The outlook is cautious; ACI presents a deep-value case with low P/S of 0.08, but execution risks and weak profitability trends pose challenges. Analyst consensus is mixed with a $13.20 price target. Key risks include competitive grocery margins, litigation overhangs, and macroeconomic headwinds affecting consumer spending.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
